Profitability: A Mixed Blessing for Celltech
Executive Summary
Celltech's early profits have come from unexciting, low growth specialty pharma products rather than from a breakthrough in its innovative biotechnology pipeline. Now, the challenge for new CEO Göran Ando is to prove that Celltech's focus remains R&D, not specialty pharmaceuticals. With few promising late-stage in-house projects other than CDP 870, generic threats to the revenue source, and the straitjacket that comes with profitability, Ando has plenty on his plate. But his experience, both broadly within the industry and with CDP 870 in particular, suggest he's well placed to take Celltech to a new level of profitability.
You may also be interested in...
Will MorphoSys Trade Profitability for More Products, More Opportunities, and More Risk?
Morphosys is a rare biotech company in that it is both an R&D driven enterprise and is profitable at the same time, thanks mostly to a variety of antibody discovery deals it has signed over the years with pharmaceutical partners. As the company brings more product candidates into the clinic will its profitability become a strategic liability, imposing limits on how much it can spend to drive products forward?
Fellner: Celltech's Revenue-Generating Model Key for Biotech
Peter Fellner, PhD, recently appointed chairman of British Biotech and outgoing CEO of Celltech Group says more of Europe's biotechs need to do what Celltech has done: find a revenue-generating business model.
Senexis Ltd.
Senexis Ltd. spun-out of the University of Manchester Institute of Science and Technology to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. In addition to being more prevalent in the older population, these diseases also share a similar underlying etiology; they are all associated with amyloidosis.